Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in Metastatic Renal Cell Carcinoma Previously Treated With Sunitinib or Bevacizumab
NCT00731211Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2008
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 18 months. Started Sep 2008; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00731211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00731211.